{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:35:07Z","timestamp":1773758107917,"version":"3.50.1"},"reference-count":161,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>p53 and p73 are critical tumor suppressors that are often inactivated in human cancers through various mechanisms. Owing to their high structural homology, the proteins have many joined functions and recognize the same set of genes involved in apoptosis and cell cycle regulation. p53 is known as the \u2018guardian of the genome\u2019 and together with p73 forms a barrier against cancer development and progression. The TP53 is mutated in more than 50% of all human cancers and the germline mutations in TP53 predispose to the early onset of multiple tumors in Li\u2013Fraumeni syndrome (LFS), the inherited cancer predisposition. In cancers where TP53 gene is intact, p53 is degraded. Despite the ongoing efforts, the treatment of cancers remains challenging. This is due to late diagnoses, the toxicity of the current standard of care and marginal benefit of newly approved therapies. Presently, the endeavors focus on reactivating p53 exclusively, neglecting the potential of the restoration of p73 protein for cancer eradication. Taken that several small molecules reactivating p53 failed in clinical trials, there is a need to develop new treatments targeting p53 proteins in cancer. This review outlines the most advanced strategies to reactivate p53 and p73 and describes drug repurposing approaches for the efficient reinstatement of the p53 proteins for cancer therapy.<\/jats:p>","DOI":"10.3390\/cancers12092717","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T02:56:43Z","timestamp":1600916203000},"page":"2717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-2942","authenticated-orcid":false,"given":"Joanna E.","family":"Zawacka-Pankau","sequence":"first","affiliation":[{"name":"Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"ref_1","unstructured":"Prasad, V.K. (2020). Malignant: How Bad Policy and Bad Evidence Harm People with Cancer, Johns Hopkins University Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmed.2019.00154","article-title":"Editorial: Drug Repurposing","volume":"6","author":"Pantziarka","year":"2019","journal-title":"Front. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41419-020-2445-9","article-title":"The p53\/MDM2\/MDMX-targeted therapies-a clinical synopsis","volume":"11","author":"Jiang","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000364","DOI":"10.1136\/jitc-2019-000364","article-title":"CAR T-cell therapy for a relapsed\/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome","volume":"8","author":"Chen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","article-title":"Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors","volume":"3","author":"Keegan","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/d41573-020-00130-z","article-title":"p53 programmes plough on","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41556-020-0559-z","article-title":"UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination","volume":"22","author":"Liu","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jmcb\/mjz060","article-title":"p53 modifications: Exquisite decorations of the powerful guardian","volume":"11","author":"Liu","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1096\/fj.02-0931com","article-title":"Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage","volume":"17","author":"Joseph","year":"2003","journal-title":"FASEB J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: Growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrc1455","article-title":"Post-translational modification of p53 in tumorigenesis","volume":"4","author":"Bode","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53","volume":"248","author":"Werness","year":"1990","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.freeradbiomed.2018.05.074","article-title":"The tumor suppressor protein p53 and the ferroptosis network","volume":"133","author":"Kang","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/0008-5472.CAN-16-2055","article-title":"p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy","volume":"76","year":"2016","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1038\/onc.2017.254","article-title":"Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2\/M phase","volume":"36","author":"Giono","year":"2017","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbabio.2008.10.005","article-title":"The mitochondrial p53 pathway","volume":"1787","author":"Vaseva","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"a026047","DOI":"10.1101\/cshperspect.a026047","article-title":"The transactivation domains of the p53 protein","volume":"7","author":"Raj","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.274.5289.948","article-title":"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain","volume":"274","author":"Kussie","year":"1996","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1006\/jmbi.1997.1078","article-title":"Molecular characterization of the hdm2-p53 interaction","volume":"269","author":"Hochkeppel","year":"1997","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.biocel.2007.03.022","article-title":"MDM2 and MDM4: p53 regulators as targets in anticancer therapy","volume":"39","author":"Toledo","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.febslet.2008.12.060","article-title":"Leucine-rich hydrophobic clusters promote folding of the N-terminus of the intrinsically disordered transactivation domain of p53","volume":"583","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmolb.2015.00039","article-title":"The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors","volume":"2","author":"Dickinson","year":"2015","journal-title":"Front. Mol. Biosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-2836(02)00326-1","article-title":"Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding","volume":"319","author":"Rippin","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16234","DOI":"10.18632\/oncotarget.24611","article-title":"Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer","volume":"9","author":"Tanaka","year":"2018","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.taap.2008.07.012","article-title":"The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances","volume":"232","author":"Krachulec","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.tibs.2003.10.004","article-title":"Functional regulation of p73 and p63: Development and cancer","volume":"28","author":"Melino","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1074\/jbc.M112.408039","article-title":"Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements","volume":"288","author":"Ethayathulla","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"W31","DOI":"10.1093\/nar\/gkaa366","article-title":"TopMatch-web: Pairwise matching of large assemblies of protein and nucleic acid chains in 3D","volume":"48","author":"Wiederstein","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jmcb\/mjz009","article-title":"Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting","volume":"11","author":"Tan","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/onc.2016.321","article-title":"Full-length p53 tetramer bound to DNA and its quaternary dynamics","volume":"36","author":"Demir","year":"2017","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mularoni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Stein, Y., Rotter, V., and Aloni-Grinstein, R. (2019). Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246197"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1101\/gad.8.15.1739","article-title":"Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential","volume":"8","author":"Barak","year":"1994","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Okamoto, K., Tsunematsu, R., Tahira, T., Sonoda, K., Asanoma, K., Yagi, H., Yoneda, T., Hayashi, K., Wake, N., and Kato, K. (2015). SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers. BMC Med. Genet., 16.","DOI":"10.1186\/s12881-015-0216-8"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33153","DOI":"10.1038\/srep33153","article-title":"MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer","volume":"6","author":"Helwa","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1073\/pnas.96.12.6937","article-title":"P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of MDM2","volume":"96","author":"Tao","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","first-page":"2816","article-title":"p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2","volume":"61","author":"Esteller","year":"2001","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/sj.onc.1204303","article-title":"p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53","volume":"20","author":"Klangby","year":"2001","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/00365590600795396","article-title":"Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)\/ARF (p14ARF) locus in urinary bladder cancer","volume":"40","author":"Kumar","year":"2006","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/onc.2008.189","article-title":"Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway","volume":"27","author":"Horn","year":"2008","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/cdd.2014.167","article-title":"Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition","volume":"22","author":"Zhou","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2020.249060","article-title":"To target the untargetable: Elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Sallman","year":"2020","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/0008-5472.CAN-05-3832","article-title":"Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3","volume":"66","author":"Patton","year":"2006","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.9.6.11067","article-title":"Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies","volume":"9","author":"Joseph","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.cdd.4401912","article-title":"Keeping p53 in check: Essential and synergistic functions of Mdm2 and Mdm4","volume":"13","author":"Marine","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/onc.2016.236","article-title":"p53 binds the mdmx mRNA and controls its translation","volume":"36","author":"Tournillon","year":"2017","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tolcher, A.W., Karim, R., Tang, Y., Ji, J., Wang, H., Meng, L., Kaiser, A., Coe, J., Liang, E., and Rosas, C. (2019, January 26\u201330). Abstract A086: Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.","DOI":"10.1158\/1535-7163.TARG-19-A086"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/38298","article-title":"p73 is a simian [correction of human] p53-related protein that can induce apoptosis","volume":"389","author":"Jost","year":"1997","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0092-8674(00)80540-1","article-title":"Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers","volume":"90","author":"Kaghad","year":"1997","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/cdd.2013.23","article-title":"Analysis of the oligomeric state and transactivation potential of TAp73\u03b1","volume":"20","author":"Luh","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/1541-7786.371.2.7","article-title":"p63 and p73: Roles in development and tumor formation","volume":"2","author":"Moll","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fonc.2016.00077","article-title":"Oncogenic Intra-p53 Family Member Interactions in Human Cancers","volume":"6","author":"Ferraiuolo","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/s41388-018-0195-2","article-title":"\u0394Np73 enhances HIF-1\u03b1 protein stability through repression of the ECV complex","volume":"37","author":"Stantic","year":"2018","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13402-017-0340-x","article-title":"\u0394Np73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells\u2014A short report","volume":"40","author":"Sakil","year":"2017","journal-title":"Cell. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Niemantsverdriet, M., Nagle, P., Chiu, R.K., Langendijk, J.A., Kampinga, H.H., and Coppes, R.P. (2012). \u0394Np73 enhances promoter activity of TGF-\u03b2 induced genes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050815"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ijc.24221","article-title":"DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells","volume":"124","author":"Vella","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cc.9.4.10668","article-title":"p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach?","volume":"9","author":"Kostecka","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1101\/gad.1339905","article-title":"p53 isoforms can regulate p53 transcriptional activity","volume":"19","author":"Bourdon","year":"2005","journal-title":"Genes Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/humu.22523","article-title":"How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: Regulators and effectors","volume":"35","author":"Candi","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1021\/pr4005508","article-title":"Analysis of TAp73-dependent signaling via omics technologies","volume":"12","author":"Marrocco","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"29881","DOI":"10.18632\/oncotarget.8935","article-title":"Metabolic pathways regulated by TAp73 in response to oxidative stress","volume":"7","author":"Agostini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/cddis.2012.27","article-title":"Regulation of p73 activity by post-translational modifications","volume":"3","author":"Conforti","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.onc.1202512","article-title":"Inactivation of the p53-homologue p73 by the mdm2-oncoprotein","volume":"18","author":"Dobbelstein","year":"1999","journal-title":"Oncogene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0960-9822(99)80367-4","article-title":"MDM2 and MDMX bind and stabilize the p53-related protein p73","volume":"9","author":"Ongkeko","year":"1999","journal-title":"Curr. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.4161\/cc.9.22.13871","article-title":"Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73","volume":"9","author":"Zdzalik","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Mavinahalli, J.N., Madhumalar, A., Beuerman, R.W., Lane, D.P., and Verma, C. (2010). Differences in the transactivation domains of p53 family members: A computational study. BMC Genom., 11.","DOI":"10.1186\/1471-2164-11-S1-S5"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1128\/MCB.20.4.1299-1310.2000","article-title":"The N-terminal domain of p73 interacts with the CH1 domain of p300\/CREB binding protein and mediates transcriptional activation and apoptosis","volume":"20","author":"Zeng","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1074\/jbc.M809211200","article-title":"c-Abl phosphorylates Hdmx and regulates its interaction with p53","volume":"284","author":"Zuckerman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1074\/jbc.274.13.8371","article-title":"c-Abl neutralizes the inhibitory effect of Mdm2 on p53","volume":"274","author":"Sionov","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15164","DOI":"10.1074\/jbc.M010484200","article-title":"Physical interaction with Yes-associated protein enhances p73 transcriptional activity","volume":"276","author":"Strano","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.cdd.4402063","article-title":"The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73","volume":"14","author":"Levy","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/sj.emboj.7600444","article-title":"The ubiquitin-protein ligase Itch regulates p73 stability","volume":"24","author":"Rossi","year":"2005","journal-title":"EMBO J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1038\/sj.onc.1202781","article-title":"Mdm2 binds p73 alpha without targeting degradation","volume":"18","author":"Bates","year":"1999","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0014-5793(01)02124-X","article-title":"MDM2 and MDMX can interact differently with ARF and members of the p53 family","volume":"490","author":"Wang","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2010.11.043","article-title":"MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells","volume":"403","author":"Kubo","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21479","DOI":"10.18632\/oncotarget.4086","article-title":"MDM2 mediates p73 ubiquitination: A new molecular mechanism for suppression of p73 function","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"19546","DOI":"10.1074\/jbc.RA118.003061","article-title":"Cytoplasmic pro-apoptotic function of the tumor suppressor p73 is mediated through a modified mode of recognition of the anti-apoptotic regulator Bcl-XL","volume":"293","author":"Yoon","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/356215a0","article-title":"Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours","volume":"356","author":"Donehower","year":"1992","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ccr.2005.02.019","article-title":"Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family","volume":"7","author":"Flores","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1101\/gad.1695308","article-title":"TAp73 knockout shows genomic instability with infertility and tumor suppressor functions","volume":"22","author":"Tomasini","year":"2008","journal-title":"Genes Dev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nature13910","article-title":"IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo","volume":"517","author":"Venkatanarayan","year":"2015","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-17-0809","article-title":"Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells","volume":"77","author":"Feeley","year":"2017","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1073\/pnas.1410609111","article-title":"TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1\u03b1 degradation","volume":"112","author":"Amelio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/ejso.1998.0626","article-title":"Infrequent somatic mutations of the p73 gene in various human cancers","volume":"25","author":"Han","year":"1999","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2005.02.2350","article-title":"DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1","volume":"24","author":"Silva","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/PGP.0b013e31821ac519","article-title":"Clinical relevance of TAp73 and \u0394Np73 protein expression in ovarian cancer: A series of 83 cases and review of the literature","volume":"30","author":"Hofstetter","year":"2011","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2011.07.030","article-title":"Targeting p73 in cancer","volume":"332","author":"Maas","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbrc.2007.06.104","article-title":"Itch inhibition regulates chemosensitivity in vitro","volume":"361","author":"Hansen","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.onc.1210707","article-title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function","volume":"27","author":"Lau","year":"2008","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.0802091105","article-title":"Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway","volume":"105","author":"Kravchenko","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/21690","article-title":"The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage","volume":"399","author":"Gong","year":"1999","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI30866","article-title":"The p63\/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers","volume":"117","author":"Leong","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/15384101.2019.1638693","article-title":"TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)","volume":"18","author":"Bunch","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Spaety, M.-E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., Yanagihara, K., Okamoto, K., Jung, A.C., and Mellitzer, G. (2019). HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73\/BIK Pathway. Cancers, 11.","DOI":"10.3390\/cancers11111747"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1484","DOI":"10.1038\/cddis.2014.408","article-title":"JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress","volume":"5","author":"Kostecka","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41598-017-05813-z","article-title":"The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells","volume":"7","author":"Dabiri","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood, 121, 4439\u20134442.","DOI":"10.1182\/blood-2013-03-490003"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1172\/JCI23540","article-title":"The $800 million pill: The truth behind the cost of new drugs","volume":"114","author":"Moore","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","article-title":"First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis","volume":"33","author":"Goldstein","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2019.05.013","article-title":"Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup","volume":"117","author":"Allodji","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/jnci\/djx235","article-title":"PanCareSurFup Consortium Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe","volume":"110","author":"Bright","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3389\/fphar.2018.00637","article-title":"\u201chard\u201d drug repurposing for precision oncology: The missing link?","volume":"9","author":"Pantziarka","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_123","first-page":"545","article-title":"The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells","volume":"9","author":"Rousselot","year":"1994","journal-title":"Oncogene"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: The repurposing drugs in oncology database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nature09526","article-title":"Selective activation of p53-mediated tumour suppression in high-grade tumours","volume":"468","author":"Junttila","year":"2010","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e1203","DOI":"10.1038\/cddis.2014.113","article-title":"High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy","volume":"5","author":"Rossi","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"16926","DOI":"10.18632\/oncotarget.4700","article-title":"Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells","volume":"6","author":"Giacobbe","year":"2015","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0140-6736(59)91311-X","article-title":"The action spectrum for skin lesions in porphyria cutanea tarda","volume":"273","author":"Magnus","year":"1959","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cheruvu, S., and Sacher, R.A. (2014). The Porphyrias and Sideroblastic Anemias. Pathobiology of Human Disease, Elsevier Inc.","DOI":"10.1016\/B978-0-12-386456-7.07904-1"},{"key":"ref_130","first-page":"541","article-title":"Autosomal recessive erythropoietic protoporphyria: A syndrome of severe photosensitivity and liver failure","volume":"88","author":"Sarkany","year":"1995","journal-title":"QJM"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/phpp.12501","article-title":"Acquired erythropoietic protoporphyria: A systematic review of the literature","volume":"36","author":"Snast","year":"2020","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bjc.1992.83","article-title":"Porphyrin metabolism in some malignant diseases","volume":"65","author":"Hafez","year":"1992","journal-title":"Br. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0304-3835(88)90211-X","article-title":"The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders","volume":"43","author":"Schoenfeld","year":"1988","journal-title":"Cancer Lett."},{"key":"ref_134","first-page":"223","article-title":"Comparative porphyrin content in tumors with contiguous non-neoplastic tissues","volume":"26","author":"Zawirska","year":"1979","journal-title":"Neoplasma"},{"key":"ref_135","first-page":"1","article-title":"Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses","volume":"6","author":"Lang","year":"2001","journal-title":"Skin Ther. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2133.2003.04898.x","article-title":"Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses","volume":"148","author":"Nakaseko","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1751-1097.2007.00276.x","article-title":"Photodynamic therapy in the treatment of actinic keratosis","volume":"84","author":"Stritt","year":"2008","journal-title":"Photochem. Photobiol."},{"key":"ref_138","first-page":"474","article-title":"Protoporphyrin IX induces apoptosis in HeLa cells prior to photodynamic treatment","volume":"59","author":"Bednarz","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1159\/000354479","article-title":"DNA damage and cell cycle arrest induced by protoporphyrin IX in sarcoma 180 cells","volume":"32","author":"Li","year":"2013","journal-title":"Cell Physiol. Biochem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1074\/jbc.M608906200","article-title":"Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner","volume":"282","author":"Issaeva","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.febslet.2010.12.004","article-title":"Targeting of p53 and its homolog p73 by protoporphyrin IX","volume":"585","author":"Sznarkowska","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41420-019-0157-7","article-title":"Protoporphyrin IX is a dual inhibitor of p53\/MDM2 and p53\/MDM4 interactions and induces apoptosis in B-cell chronic leukemia cells","volume":"5","author":"Jiang","year":"2019","journal-title":"Cell Death Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13008-018-0043-3","article-title":"Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells","volume":"13","author":"Sznarkowska","year":"2018","journal-title":"Cell Div."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"FSO366","DOI":"10.4155\/fsoa-2018-0082","article-title":"Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in TP53 mutant pancreatic tumors","volume":"5","author":"Acedo","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Huang","year":"2012","journal-title":"Genes Dev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cell.2019.06.005","article-title":"BACH1 stabilization by antioxidants stimulates lung cancer metastasis","volume":"178","author":"Wiel","year":"2019","journal-title":"Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/nsmb.1516","article-title":"Bach1 inhibits oxidative stress-induced cellular senescence by impeding p53 function on chromatin","volume":"15","author":"Dohi","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1349-7006.2012.02244.x","article-title":"Bach1-mediated suppression of p53 is inhibited by p19(ARF) independently of MDM2","volume":"103","author":"Nishizawa","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/carcin\/23.6.949","article-title":"High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter","volume":"23","author":"Sohn","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41418-019-0387-5","article-title":"The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity","volume":"27","author":"Espinoza","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/gutjnl-2015-309996","article-title":"Spectral biomarkers for chemoprevention of colonic neoplasia: A placebo-controlled double-blinded trial with aspirin","volume":"66","author":"Roy","year":"2017","journal-title":"Gut"},{"key":"ref_152","first-page":"511","article-title":"Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis","volume":"23","author":"Bousserouel","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/carcin\/22.9.1393","article-title":"Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak","volume":"22","author":"Zhou","year":"2001","journal-title":"Carcinogenesis"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1007\/s13277-015-4438-3","article-title":"Aspirin acetylates wild type and mutant p53 in colon cancer cells: Identification of aspirin acetylated sites on recombinant p53","volume":"37","author":"Ai","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1038\/s41467-018-05805-1","article-title":"Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers","volume":"9","author":"Kumar","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Mizuno","year":"2012","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014Mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/MCB.00670-13","article-title":"AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity","volume":"34","author":"He","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bbrc.2015.07.117","article-title":"p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells","volume":"464","author":"Li","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(20)30424-1","article-title":"Drug repurposing for cancer treatments: A well-intentioned, but misguided strategy","volume":"21","author":"Tran","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:22Z","timestamp":1760177542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":161,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["cancers12092717"],"URL":"https:\/\/doi.org\/10.3390\/cancers12092717","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202008.0729.v1","asserted-by":"object"},{"id-type":"doi","id":"10.20944\/preprints202008.0729.v2","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]}}}